Mylan

U.S. health officials on Thursday approved a new generic version of EpiPen, the emergency allergy medication that triggered a public backlash due to its…

In testimony prepared for a congressional hearing, Mylan CEO Heather Bresch says the company makes about $50 in profit on each EpiPen. Analysts say it's still a hefty margin.

Heather Bresch, the head of pharmaceutical company Mylan, is defending the cost for life-saving EpiPens, signaling the company has no plans to lower…